PYXIS ONCOLOGY INC (PYXS) Stock News

USA - NASDAQ:PYXS - US7473241013 - Common Stock

3.46 USD

+0.08 (+2.37%)

Last: 10/24/2025, 8:00:01 PM

3.46 USD

0 (0%)

After Hours: 10/24/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PYXS Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Pyxis Oncology

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

13 days ago - By: Pyxis Oncology

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

18 days ago - By: Pyxis Oncology

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

18 days ago - By: Pyxis Oncology

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

a month ago - By: Zacks Investment Research

Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?

20 days ago - By: Benzinga - Mentions: SNWV ONMD ORMP TXMD ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Pyxis Oncology

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Pyxis Oncology

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: ALLO BMY PFE LLY ...

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines

2 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in September Investor and Industry Conferences

2 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in September Investor and Industry Conferences

2 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Pyxis Oncology

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Pyxis Oncology

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

6 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

6 months ago - By: Pyxis Oncology

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

6 months ago - By: Pyxis Oncology

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

6 months ago - By: Zacks Investment Research - Mentions: ESPR HRTX AUPH PSTV

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

7 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

7 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

7 months ago - By: Pyxis Oncology

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

7 months ago - By: Pyxis Oncology

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

7 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7 months ago - By: Pyxis Oncology

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

8 months ago - By: Pyxis Oncology

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

8 months ago - By: Pyxis Oncology

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

8 months ago - By: Pyxis Oncology

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

9 months ago - By: Pyxis Oncology

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

9 months ago - By: Pyxis Oncology

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

10 months ago - By: Benzinga

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

10 months ago - By: Pyxis Oncology

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

10 months ago - By: Pyxis Oncology

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201